Alchemia announces appointment of Santo Costa as chairman

11 February 2014

Australia-based biotech company Alchemia (ASX:ACL) has announced the appointment of Santo Costa as non-executive chairman of the Board of Directors, effective March 1.

Mr Costa (pictured) brings to Alchemia international experience serving in senior leadership roles across the life sciences industry. Over a 30 year period, Mr Costa has held top executive positions including President and Chief Operating Officer of Quintiles Transnational and Senior Vice President, Administration and General Counsel of Glaxo, where he was on the company’s Board of Directors and Executive Committee.

Nathan Drona, who has served as Alchemia’s chairman since July 15, 2013, will remain on the board as a non-executive director.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK